<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00537901</url>
  </required_header>
  <id_info>
    <org_study_id>RAC #2041-082</org_study_id>
    <nct_id>NCT00537901</nct_id>
  </id_info>
  <brief_title>First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study</brief_title>
  <official_title>First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Faisal Specialist Hospital &amp; Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Faisal Specialist Hospital &amp; Research Center</source>
  <brief_summary>
    <textblock>
      First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>overall</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>overall</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">100</enrollment>
  <condition>Colonic Neoplasms</condition>
  <condition>Rectal Neoplasms</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>First-Line Bevacizumab and Chemotherapy</intervention_name>
    <description>Chemotherapy</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Chemotherapy</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with metastatic cancer of colon or rectum
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shouki Bazarbashi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KFSH &amp; RC</affiliation>
  </overall_official>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2007</study_first_submitted>
  <study_first_submitted_qc>October 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2007</study_first_posted>
  <last_update_submitted>December 16, 2015</last_update_submitted>
  <last_update_submitted_qc>December 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Faisal Specialist Hospital &amp; Research Center</investigator_affiliation>
    <investigator_full_name>Dr. Naeem A. Chaudhri</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Colon and Rectum Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

